Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Italy flag Italy · Delayed Price · Currency is EUR
54.20
-0.10 (-0.18%)
Sep 5, 2025, 9:44 AM CET

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Specialty & Primary Care
1.51B
Log In
Log In
Log In
Log In
Upgrade
Specialty & Primary Care Growth
5.18%
Log In
Log In
Log In
Log In
Upgrade
Rare Diseases
833.86M
Log In
Log In
Log In
Log In
Upgrade
Rare Diseases Growth
23.48%
Log In
Log In
Log In
Log In
Upgrade
Pharmaceutical Chemicals
58.47M
Log In
Log In
Log In
Log In
Upgrade
Pharmaceutical Chemicals Growth
10.99%
Log In
Log In
Log In
Log In
Upgrade
Other
2.28B
Log In
Log In
Log In
Log In
Upgrade
Other Growth
11.53%
Log In
Log In
Log In
Log In
Upgrade
Cardiovascular
385.21M
Log In
Log In
Log In
Log In
Upgrade
Cardiovascular Growth
7.86%
Log In
Log In
Log In
Log In
Upgrade
Urology and Uro-Oncology
399.94M
Log In
Log In
Log In
Log In
Upgrade
Urology and Uro-Oncology Growth
13.21%
Log In
Log In
Log In
Log In
Upgrade
Gastrointestinal
217.50M
Log In
Log In
Log In
Log In
Upgrade
Gastrointestinal Growth
2.46%
Log In
Log In
Log In
Log In
Upgrade
Cough and Cold
137.28M
Log In
Log In
Log In
Log In
Upgrade
Cough and Cold Growth
-0.97%
Log In
Log In
Log In
Log In
Upgrade
Other Treatment Areas
309.31M
Log In
Log In
Log In
Log In
Upgrade
Other Treatment Areas Growth
-3.48%
Log In
Log In
Log In
Log In
Upgrade
Hema-Oncology
253.23M
Log In
Log In
Log In
Log In
Upgrade
Hema-Oncology Growth
51.33%
Log In
Log In
Log In
Log In
Upgrade
Endocrinology
321.69M
Log In
Log In
Log In
Log In
Upgrade
Endocrinology Growth
21.92%
Log In
Log In
Log In
Log In
Upgrade
Metabolic and Other Areas
258.94M
Log In
Log In
Log In
Log In
Upgrade
Metabolic and Other Areas Growth
1.55%
Log In
Log In
Log In
Log In
Upgrade
Zanidip
-
Log In
Log In
Log In
Log In
Upgrade
Zanidip Growth
-
Log In
Log In
Log In
Log In
Upgrade
Zanipress
-
Log In
Log In
Log In
Log In
Upgrade
Zanipress Growth
-
Log In
Log In
Log In
Log In
Upgrade
Urorec
-
Log In
Log In
Log In
Log In
Upgrade
Urorec Growth
-
Log In
Log In
Log In
Log In
Upgrade
Livazo
-
Log In
Log In
Log In
Log In
Upgrade
Livazo Growth
-
Log In
Log In
Log In
Log In
Upgrade
Drugs for Rare Diseases
-
Log In
Log In
Log In
Log In
Upgrade
Drugs for Rare Diseases Growth
-
Log In
Log In
Log In
Log In
Upgrade
Seloken/Logimax
-
Log In
Log In
Log In
Log In
Upgrade
Seloken/Logimax Growth
-
Log In
Log In
Log In
Log In
Upgrade
Other Corporate Products
-
Log In
Log In
Log In
Log In
Upgrade
Other Corporate Products Growth
-
Log In
Log In
Log In
Log In
Upgrade
OTC
-
Log In
Log In
Log In
Log In
Upgrade
OTC Growth
-
Log In
Log In
Log In
Log In
Upgrade
Local Product Portfolios
-
Log In
Log In
Log In
Log In
Upgrade
Local Product Portfolios Growth
-
Log In
Log In
Log In
Log In
Upgrade
Other Product
-
Log In
Log In
Log In
Log In
Upgrade
Other Product Growth
-
Log In
Log In
Log In
Log In
Upgrade
Eligard
-
Log In
Log In
Log In
Log In
Upgrade
Eligard Growth
-
Log In
Log In
Log In
Log In
Upgrade
Other
2.28B
Log In
Log In
Log In
Log In
Upgrade
Other Growth
11.53%
Log In
Log In
Log In
Log In
Upgrade

EBIT by Product

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Other
59.50M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-3.23%
Log In
Log In
Log In
Log In
Upgrade
Specialty & Primary Care Operating Income
426.73M
Log In
Log In
Log In
Log In
Upgrade
Specialty & Primary Care Operating Income Growth
-2.92%
Log In
Log In
Log In
Log In
Upgrade
Rare Diseases Operating Income
212.13M
Log In
Log In
Log In
Log In
Upgrade
Rare Diseases Operating Income Growth
36.18%
Log In
Log In
Log In
Log In
Upgrade
Other
59.50M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-3.23%
Log In
Log In
Log In
Log In
Upgrade

EBITDA by Product

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Specialty & Primary Care EBITDA
524.44M
Log In
Log In
Log In
Log In
Upgrade
Specialty & Primary Care EBITDA Growth
2.23%
Log In
Log In
Log In
Log In
Upgrade
Rare Diseases EBITDA
341.33M
Log In
Log In
Log In
Log In
Upgrade
Rare Diseases EBITDA Growth
26.19%
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Italy
336.26M
Log In
Log In
Log In
Log In
Upgrade
Italy Growth
1.11%
Log In
Log In
Log In
Log In
Upgrade
International
2.01B
Log In
Log In
Log In
Log In
Upgrade
International Growth
13.36%
Log In
Log In
Log In
Log In
Upgrade
Europe
1.65B
Log In
Log In
Log In
Log In
Upgrade
Europe Growth
-
Log In
Log In
Log In
Log In
Upgrade
Asia and Oceania
156.01M
Log In
Log In
Log In
Log In
Upgrade
Asia and Oceania Growth
-
Log In
Log In
Log In
Log In
Upgrade
America
477.46M
Log In
Log In
Log In
Log In
Upgrade
America Growth
-
Log In
Log In
Log In
Log In
Upgrade
Africa
58.03M
Log In
Log In
Log In
Log In
Upgrade
Africa Growth
-
Log In
Log In
Log In
Log In
Upgrade

Other

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Specialty & Primary Care Like-For-Like Growth
5.70%
Log In
Log In
Log In
Log In
Upgrade
Rare Diseases Like-For-Like Growth
15.70%
Log In
Log In
Log In
Log In
Upgrade
Total Like-For-Like Growth
9.20%
Log In
Log In
Log In
Log In
Upgrade